Status:

COMPLETED

Therapy for Pediatric Hodgkin Lymphoma

Lead Sponsor:

St. Jude Children's Research Hospital

Conditions:

Hodgkin Lymphoma

Eligibility:

All Genders

Up to 21 years

Phase:

PHASE2

Brief Summary

With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxi...

Detailed Description

This study will evaluate the following objectives: Primary Objectives: 1. To evaluate the efficacy of 4 cycles of VAMP chemotherapy alone in patients with favorable risk Hodgkin's disease who achiev...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Eligible patients must have histologically confirmed previously untreated Hodgkin's disease (Patients receiving limited emergent RT or steroid therapy because of cardiopulmonary decompensation or spinal cord compression will be eligible for protocol enrollment).
  • Patients must be 21 years of age or younger
  • Ann Arbor stages IIB-IV
  • No prior treatment.
  • No pregnant or lactating women.
  • Signed informed consent
  • If re-evaluation of a patient's disease shows favorable risk features or intermediate risk features, the patient will be removed from the HOD99 study and consented to the respective HOD08 or HOD05 study.
  • Inclusion: treatment of favorable risk features:
  • Ann Arbor IA or IIA with:
  • Non-bulky mediastinal disease (\<33% mediastinal to thoracic ratio on chest x ray)
  • Ann Arbor stage IA or IIA with any of the following features: (1) "E" lesions (s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)
  • Inclusion: unfavorable risk features:
  • Stage must be classified as one of the following:
  • Ann Arbor stage IIB, IIIB, or any IV

Exclusion

    Key Trial Info

    Start Date :

    March 2 2000

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 5 2021

    Estimated Enrollment :

    296 Patients enrolled

    Trial Details

    Trial ID

    NCT00145600

    Start Date

    March 2 2000

    End Date

    November 5 2021

    Last Update

    October 20 2022

    Active Locations (5)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (5 locations)

    1

    Stanford University

    Palo Alto, California, United States, 94304

    2

    Maine Children's Cancer Program

    Portland, Maine, United States, 04102-3175

    3

    Dana Farber Cancer Institute

    Boston, Massachusetts, United States, 02115

    4

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02115